Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

CEL SCI CORP

CVM · NYSE · CIK 0000725363 · Healthcare · Biotechnology

INSIDER SIGNAL

49.5 / 100

1 buyers · 3 purchase transaction lines · $617.0K gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeModerate
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35
Purchase size+15.4 / 25
Role+13.0 / 20
Recency+4.1 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Role scores low · most senior buyer: Chief Executive Officer (CEO, chair and 10% owners score lowest)

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
KERSTEN GEERT RChief Executive Officer
●●○●○
TALOR EYALChief Scientific Officer
○○
PRICHEP PATRICIA BChief Financial Officer
○○
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: KERSTEN GEERT R · $617.0K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-05-13–2026-05-14

Roles in the peak window: Chief Executive Officer. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

49.5 / 100

Latest recorded score

↓ -0.2 ptsversus the previous recorded snapshot
  1. 50.0
  2. 50.0
  3. 49.8
  4. 49.7
  5. 49.5

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

5Purchases
0Sales
9Other Form 4 lines
14SEC filings · 365 days
BUYING3 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER6 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot detected in parsed evidence

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
+27.6%
3M
+59.0%
6M
-52.3%
12M
-80.7%

Volatility & liquidity

Volatility
128.6%
Beta
—
Avg daily value
USD 469,308

Valuation

Market cap
USD 34.1M
P/E
—

Fundamentals

Profit margin
—
ROE
-159.2%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, ROE · Fiscal year ended: 2025-09-30 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-10 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
592,420
Previous report
619,262
Avg daily volume
143,193
Days to cover
4.1

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-25KERSTEN GEERT RPurchase (P)Common Stock100,000USD 1.38USD 138,000SEC filing ↗
2026-05-14KERSTEN GEERT RPurchase (P)Common Stock300,000USD 1.20USD 360,000SEC filing ↗
2026-05-13KERSTEN GEERT RPurchase (P)Common Stock100,000USD 1.19USD 119,000SEC filing ↗
2026-01-22KERSTEN GEERT RPurchase (P)Common Stock38,023USD 5.26USD 200,001SEC filing ↗
2025-12-04KERSTEN GEERT RPurchase (P)Common Stock8,389USD 5.96USD 49,998SEC filing ↗
2025-07-25Watson Robert EugenePurchase (P)Common Stock2,919USD 6.85USD 19,995SEC filing ↗
2025-07-25KERSTEN GEERT RPurchase (P)Common Stock29,197USD 6.85USD 199,999SEC filing ↗
2024-05-08Watson Robert EugenePurchase (P)Common Stock20,000USD 1.39USD 27,800SEC filing ↗
2024-05-08PRICHEP PATRICIA BPurchase (P)Common Stock8,000USD 1.39USD 11,120SEC filing ↗
2024-05-08KERSTEN GEERT RPurchase (P)Common Stock30,000USD 1.39USD 41,700SEC filing ↗
2021-07-06Watson Robert EugenePurchase (P)Common Stock1,250USD 8.00USD 10,000SEC filing ↗
2021-07-06KERSTEN GEERT RPurchase (P)Common Stock25,000USD 8.00USD 200,000SEC filing ↗
2021-07-06BAILLAVOINE BRUNO JEAN-MARIEPurchase (P)Common Stock1,250USD 8.00USD 10,000SEC filing ↗
2021-06-28YOUNG PETER RPurchase (P)Common Stock3,000USD 12.66USD 37,980SEC filing ↗
2020-12-11YOUNG PETER RPurchase (P)Common Stock100USD 14.24USD 1,424SEC filing ↗

Form 4 evidence

14 transaction lines in the latest 365-day window; 119 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-30TALOR EYALAward / grant (A)Common Stock1,165USD 2.06USD 2,400SEC filing ↗
2026-09-30PRICHEP PATRICIA BAward / grant (A)Common Stock2,082USD 2.06USD 4,289SEC filing ↗
2026-09-30KERSTEN GEERT RAward / grant (A)Common Stock2,621USD 2.06USD 5,399SEC filing ↗
Show recent Form 4 evidence (14 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-30TALOR EYALAward / grant (A)Common Stock1,165USD 2.06USD 2,400SEC filing ↗
2026-09-30PRICHEP PATRICIA BAward / grant (A)Common Stock2,082USD 2.06USD 4,289SEC filing ↗
2026-09-30KERSTEN GEERT RAward / grant (A)Common Stock2,621USD 2.06USD 5,399SEC filing ↗
2026-08-25KERSTEN GEERT RPurchase (P)Common Stock100,000USD 1.38USD 138,000SEC filing ↗
2026-06-30TALOR EYALAward / grant (A)Common Stock2,307USD 1.04USD 2,399SEC filing ↗
2026-06-30PRICHEP PATRICIA BAward / grant (A)Common Stock4,125USD 1.04USD 4,290SEC filing ↗
2026-06-30KERSTEN GEERT RAward / grant (A)Common Stock5,192USD 1.04USD 5,400SEC filing ↗
2026-05-14KERSTEN GEERT RPurchase (P)Common Stock300,000USD 1.20USD 360,000SEC filing ↗
2026-05-13KERSTEN GEERT RPurchase (P)Common Stock100,000USD 1.19USD 119,000SEC filing ↗
2026-01-22KERSTEN GEERT RPurchase (P)Common Stock38,023USD 5.26USD 200,001SEC filing ↗
2025-12-31TALOR EYALAward / grant (A)Common Stock456USD 5.26USD 2,399SEC filing ↗
2025-12-31PRICHEP PATRICIA BAward / grant (A)Common Stock815USD 5.26USD 4,287SEC filing ↗
2025-12-31KERSTEN GEERT RAward / grant (A)Common Stock998USD 5.26USD 5,249SEC filing ↗
2025-12-04KERSTEN GEERT RPurchase (P)Common Stock8,389USD 5.96USD 49,998SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerCVM
CIK0000725363
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNYSE

Data coverage

Local Form 4 history119 transaction lines from 2020-01-10 to 2026-09-30
27 P purchase lines · 3 S sale lines · 89 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.